B cell depletion therapies in autoimmune disease: advances and mechanistic insights
DSW Lee, OL Rojas, JL Gommerman - Nature reviews Drug discovery, 2021 - nature.com
In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …
Ocrelizumab: a review in multiple sclerosis
YN Lamb - Drugs, 2022 - Springer
Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
The COVID-19 pandemic and the use of MS disease-modifying therapies
G Giovannoni, C Hawkes… - … sclerosis and related …, 2020 - msard-journal.com
Maria was distraught after reading about the 'potential'epidemic, yet to happen, and the
horror stories on Facebook needing reassurance and certainty about what she should do …
horror stories on Facebook needing reassurance and certainty about what she should do …
Early aggressive treatment approaches for multiple sclerosis
A Simpson, EM Mowry, SD Newsome - Current treatment options in …, 2021 - Springer
Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Background: Ofatumumab is approved for the treatment of relapsing multiple sclerosis
(RMS). Ongoing safety reporting is crucial to understand its long-term benefit–risk profile …
(RMS). Ongoing safety reporting is crucial to understand its long-term benefit–risk profile …
Treatment optimization in multiple sclerosis: Canadian MS working group recommendations
MS Freedman, V Devonshire, P Duquette… - Canadian Journal of …, 2020 - cambridge.org
The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
Immune system detects foreign pathogens, distinguishes them from self-antigens and
responds to defend human body. When this self-tolerance is disrupted, the overactive …
responds to defend human body. When this self-tolerance is disrupted, the overactive …
Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis
Background and Objectives To report safety of ocrelizumab (OCR) up to 7 years in patients
with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) …
with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) …
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study
Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, is approved
in several countries for relapsing multiple sclerosis (RMS). Objective: To demonstrate the …
in several countries for relapsing multiple sclerosis (RMS). Objective: To demonstrate the …